Xenon Pharmaceuticals (XENE) Total Current Liabilities (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Total Current Liabilities of $39.8 million for Q1 2026, up 24.31% year-over-year from $32.0 million in Q1 2025, and down 4.73% quarter-over-quarter from $41.8 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Total Current Liabilities (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Total Current Liabilities for 14 consecutive years, with $39.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 24.31% year-over-year to $39.8 million; the TTM figure through Mar 2026 stood at $39.8 million (up 24.31% YoY), while the FY2025 annual figure was $41.8 million, up 17.43% from the prior year.
- Total Current Liabilities slipped to $39.8 million in Q1 2026 per XENE's latest filing, from $41.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $41.8 million in Q4 2025 and bottomed at $8.0 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $27.4 million across 5 years, with a median of $28.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 30.54% — and 2023, when it soared 181.77%.
- Xenon Pharmaceuticals' Total Current Liabilities stood at $22.7 million in 2022, then grew by 20.13% to $27.3 million in 2023, then jumped by 30.5% to $35.6 million in 2024, then climbed by 17.43% to $41.8 million in 2025, then fell by 4.73% to $39.8 million in 2026.
- Business Quant data shows XENE's Total Current Liabilities at $39.8 million in Q1 2026, $41.8 million in Q4 2025, and $38.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 45.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.01 Mn |
| Mar 31, 2026 | 39.82 Mn |
| Dec 31, 2025 | 41.79 Mn |
| Sep 30, 2025 | 38.34 Mn |
| Jun 30, 2025 | 33.05 Mn |
| Mar 31, 2025 | 32.03 Mn |
| Dec 31, 2024 | 35.59 Mn |
| Sep 30, 2024 | 29.70 Mn |
| Jun 30, 2024 | 31.29 Mn |
| Mar 31, 2024 | 22.22 Mn |
| Dec 31, 2023 | 27.27 Mn |
| Sep 30, 2023 | 24.74 Mn |
| Jun 30, 2023 | 28.16 Mn |
| Mar 31, 2023 | 22.49 Mn |
| Dec 31, 2022 | 22.70 Mn |
| Sep 30, 2022 | 15.54 Mn |
| Jun 30, 2022 | 13.74 Mn |
| Mar 31, 2022 | 7.98 Mn |
| Dec 31, 2021 | 14.32 Mn |
| Sep 30, 2021 | 12.86 Mn |